ISU Abxis Co., Ltd. Logo

ISU Abxis Co., Ltd.

Develops antibody-based immunotherapies for oncology and rare diseases.

086890 | KO

Overview

Corporate Details

ISIN(s):
KR7086890001
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 대왕판교로712번길 22, 씨동 5층 (삼평동, 글로벌알앤디센터), 성남시

Description

ISU Abxis is a biopharmaceutical company specializing in the research and development of innovative biomedicines, primarily engineered antibody-based immunotherapies. Founded in 2001, the company leverages genetic recombination technology to create novel treatments. Its pipeline is focused on addressing significant unmet medical needs in oncology and rare diseases. Key development programs include therapeutics for cancers like Head and Neck Squamous Cell Carcinoma (ISU104) and treatments for rare genetic disorders such as Fabry disease (Fabagal). The company is dedicated to developing advanced antibody-based therapeutics to improve the quality of life for patients with difficult-to-treat conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-08 00:00
기업설명회(IR)개최
Korean 6.7 KB
2025-08-22 00:00
기업설명회(IR)개최
Korean 6.7 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.0 MB
2025-08-11 00:00
기업설명회(IR)개최
Korean 6.7 KB
2025-08-08 00:00
영업(잠정)실적(공정공시)
Korean 14.3 KB
2025-07-21 00:00
주식등의대량보유상황보고서(일반)
Korean 103.4 KB
2025-07-14 00:00
전환청구권행사
Korean 9.4 KB
2025-07-14 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.1 KB
2025-07-11 00:00
전환청구권행사
Korean 14.0 KB
2025-07-08 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-07-08 00:00
주식등의대량보유상황보고서(일반)
Korean 99.4 KB
2025-06-30 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.8 KB
2025-06-30 00:00
주식등의대량보유상황보고서(일반)
Korean 107.4 KB
2025-06-24 00:00
기업설명회(IR)개최
Korean 6.7 KB
2025-06-19 00:00
[기재정정]단일판매ㆍ공급계약체결
Korean 18.0 KB

Automate Your Workflow. Get a real-time feed of all ISU Abxis Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ISU Abxis Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ISU Abxis Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.